Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial por Walter Suárez Carmona | Oct 3, 2025
Epidemiology, Genetic Etiology, and Intervention of Premature Ovarian Insufficiency por Walter Suárez Carmona | Oct 2, 2025
Mechanisms and therapeutic insights into MASH-associated fibrosis por Walter Suárez Carmona | Oct 2, 2025
Anabolic-androgenic steroids among recreational athletes and cardiovascular risk por Walter Suárez Carmona | Oct 2, 2025
